Recce Pharmaceuticals (ASX:RCE) has announced promising new preclinical results demonstrating that its lead anti-infective, RECCE 327, delivered via inhalation, can significantly reduce bacterial burden in a validated mouse model of hospital- and ventilator-acquired pneumonia. …
Recce reports strong preclinical efficacy for inhaled R327 in hospital-acquired pneumonia model
November 26, 2025 Australian Biotech
Latest Video
New Stories
-
Peter Mac taps Sydney manufacturer to test its solid tumour CAR T therapy
October 14, 2026 - - Latest News -
Priceline Pharmacy puts its name on the Diamonds as netball rides record growth
October 14, 2026 - - Latest News -
'Maximising off patent medicines and why the PBS needs a biosimilar strategy'
October 14, 2026 - - Latest News -
Until the law changes what the committee is instructed to weigh, these processes will deliver nothing
October 14, 2026 - - Latest News -
The PBS stands alone as the only major health and disability program going backwards
October 13, 2026 - - Latest News -
GBMA's Nikki Lorenz returns from global generics talks with WHO and WTO
October 13, 2026 - - Latest News -
Australian children with cancer are missing out on trials adults can access
October 13, 2026 - - Latest News